U.S. markets closed

ADVM Jun 2021 7.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
5.800.00 (0.00%)
As of 9:30AM EST. Market open.
Full screen
Previous Close5.80
Open5.80
Bid5.40
Ask7.50
Strike7.50
Expire Date2021-06-18
Day's Range5.80 - 5.80
Contract RangeN/A
Volume1
Open Interest49
  • Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
    GlobeNewswire

    Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results

    Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this callREDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, March 1, 2021 at 1:30 pm PT/4:30 pm ET to highlight significant progress in the development plans for ADVM-022 in wet AMD, recent business progress, and report fourth quarter 2020 financial results. Key Opinion Leader, Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call. The live webcast will be accessible under Events and Presentations in the Investors section of the company's website. To participate in the conference call, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to the “Adverum Biotechnologies’ Conference Call.” It is recommended call participants dial in 15 minutes in advance. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days. About Adverum Biotechnologies Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com. CONTACT: Investor and Media Inquiries: Investors: Myesha Lacy Adverum Biotechnologies, Inc. mlacy@adverum.com 1-650-304-3892 Media: Andrea Cohen Sam Brown Inc. andreacohen@sambrown.com 917-209-7163

  • GlobeNewswire

    Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors

    REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Reed V. Tuckson, M.D., FACP as an independent member of Adverum’s Board of Directors. Dr. Tuckson brings extensive policy knowledge from his experience in multiple facets of the healthcare industry, including a 13-year tenure in senior leadership positions at UnitedHealth Group, where he served as chief of medical affairs. “Reed’s leadership and deep healthcare policy expertise, from clinical services administration and medical policies to consumer health engagement, will be a tremendous asset to Adverum as we prepare for global commercialization of ADVM-022, the first mass market gene therapy product for the treatment of patients with wet AMD and DME,” said Laurent Fischer, M.D., chief executive officer at Adverum Biotechnologies. “During his career, Reed has exhibited a commitment to putting patients first while enhancing quality and efficiency in care delivery as exemplified by his recent involvement in improving access to COVID-19 vaccines in disproportionally impacted minority populations. With Reed and the recent appointment of Dawn Svoronos, we have strengthened our breadth of leadership in commercialization and healthcare policy at the director level. Additionally, we are committed to leading our industry with a highly diverse and qualified board. We extend a warm welcome to Reed.” “This is an incredibly exciting time to join Adverum as a director,” said Dr. Tuckson. “ADVM-022 has the potential to dramatically reduce the treatment and societal burden for millions of patients worldwide living with wet AMD and DME, two leading causes of blindness. This is particularly important in minority and underserved communities where the frequency of current standard-of-care treatment can create barriers to access that can lead to unintended vision loss. I am honored to play a role in Adverum’s continued development of ADVM-022 and look forward to bringing a fully encompassing approach to patient health and well-being in support of the company’s mission to preserve patient sight for life.” Since 2013, Dr. Tuckson has held the position of managing director of Tuckson Health Connections, a private consulting company. Previously, he served as executive vice president and chief of medical affairs, as well as senior vice president of clinical affairs, for UnitedHealth Group, where he oversaw the company’s medical and clinical-related policies and activities. Dr. Tuckson has also held positions as senior vice president for professional standards of the American Medical Association; president of the Charles R. Drew University of Medicine and Science in Los Angeles, California; senior vice president for programs of the March of Dimes Birth Defects Foundation; and Commissioner of Public Health for the District of Columbia. A recognized leader in his field, Dr. Tuckson serves on the board of directors of CTI BioPharma Corp., Alliance for Health Policy, and Project Sunshine. Additionally, he is a member of the advisory board of the National Institutes of Health Clinical Center and serves on several committees of the National Academy of Medicine. Dr. Tuckson received a B.S. from Howard University and an M.D. from Georgetown University School of Medicine. He completed the University of Pennsylvania Hospital’s General Internal Medicine Residency and Fellowship programs. About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com. Forward-looking StatementsStatements contained in this press release regarding the events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding: the potential for ADVM-022 in treating patients with wet AMD and DME; Adverum’s expectations as to the advancement and commercial potential of ADVM-022; and Adverum’s expectations as to the benefits it expects from the addition of Dr. Tuckson. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the results of early clinical trials not always being predictive of future results; the potential for future complications or side effects in connection with use of ADVM-022. Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q filed with the SEC on November 5, 2020 under the heading “Risk Factors.” All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Investor Relations Contact Myesha Lacy Vice President, Investor Relations and Corporate Communications Adverum Biotechnologies, Inc. T: 650-649-1257 E: mlacy@adverum.com Media Contact Andrea Cohen Sam Brown Inc. T: 917-209-7163 E: andreacohen@sambrown.com

  • Adverum Appoints Christopher J. DeRespino as Chief Business Officer
    GlobeNewswire

    Adverum Appoints Christopher J. DeRespino as Chief Business Officer

    REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Christopher J. DeRespino as chief business officer, effective immediately. In this newly created position, Mr. DeRespino will lead corporate strategy and global business development efforts reporting to Laurent Fischer, M.D., Adverum’s chief executive officer. “Over the course of his career, which spans more than 15 years in the pharmaceutical industry, Chris has demonstrated an ability to drive business growth and value at leading companies in our sector,” said Laurent Fischer, M.D., chief executive officer at Adverum Biotechnologies. “Chris is joining our organization at an important time and we are excited to welcome him to our executive team. His leadership experience and proven track record identifying and fostering strategic alliances, coupled with his in-depth understanding of key opportunities and challenges, will be invaluable. We look forward to Chris’ contributions as we broaden our pipeline and advance our pivotal development plans and pre-commercialization efforts for ADVM-022 for the treatment of wet AMD.” “Adverum’s vision to establish its ocular gene therapy as a one-time treatment that preserves patient sight for life is driven by its lead therapy ADVM-022, which has demonstrated the potential to transform patient care,” said Chris DeRespino. “I’m inspired by the team’s deep ophthalmology and gene therapy expertise. I’m eager to apply my experience advancing corporate business objectives and partnering with my colleagues to broaden Adverum’s development pipeline to help patients who suffer from serious and rare ocular diseases.”Mr. DeRespino joins Adverum from Amgen where he spent eight years, most recently as executive director of business development, responsible for negotiating product transactions and partnerships and co-leading the business development transactions function as a member of Amgen’s business development leadership team. Prior to Amgen, Mr. DeRespino served as director, asset acquisition/business development at Onyx Pharmaceuticals, which Amgen acquired for $10.4 billion. Mr. DeRespino joined Onyx from Pfizer, where he was director of business development evaluation and strategy and supported numerous transactions across a wide spectrum of therapeutic areas and geographies. Mr. DeRespino began his career in management consulting at CSC Global Health Solutions where he collaborated with pharmaceutical organizations and leading academic medical centers on strategic plans, investment decisions, potential partnerships, and operational initiatives. Mr. DeRespino earned his MBA from New York University, Leonard N. Stern School of Business and a B.S.E. in biomedical engineering from Johns Hopkins University. On February 18, 2021, the company granted Mr. DeRespino a stock option to purchase 425,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to his entering into employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on the Nasdaq Stock Market on the grant date, and will vest over four years, subject to his continued service with Adverum. About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com. Forward-looking StatementsStatements contained in this press release regarding the events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding: the potential for ADVM-022 in treating patients with wet AMD and DME; Adverum’s expectations regarding advancing its pivotal development plans and pre-commercialization efforts for ADVM-022 for the treatment of wet age-related macular degeneration; Adverum’s expectations regarding expansion of its pipeline and the commercial potential of ADVM-022; and Adverum’s expectations as to the benefits it expects from the addition of Mr. DeRespino. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the results of early clinical trials not always being predictive of future results; the potential for future complications or side effects in connection with use of ADVM-022. Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q filed with the SEC on November 5, 2020 under the heading “Risk Factors.” All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Investor Relations Contact Myesha Lacy Vice President, Investor Relations and Corporate Communications Adverum Biotechnologies, Inc. T: 650-649-1257 E: mlacy@adverum.com Media Contact Andrea Cohen Sam Brown Inc. T: 917-209-7163 E: andreacohen@sambrown.com